Pro/Anti-Inflammatory Cytokine Imbalance in Postischemic Left Ventricular Remodeling

Table 1

Baseline characteristics of patients.

	Remodeling patients ($n=20$)	Not remodeling patients ($n=20$)	$P$
Age, y	$64\pm 7$	$63\pm 9$	NS
Male : female	13/7	12/8	NS
Risk factors, $n$ (%)
Familiarity	12 (60%)	10 (50%)	NS
Smoke	4 (20%)	6 (30%)	NS
Hypertension	2 (10%)	3(15%)	NS
Diabetes	0	0	NS
Hypercolesterolemia	4 (20%)	4 (20%)	NS
Anterior and/or lateral infarction	14 (70%)	13 (65%)	NS
Q wave at admission	12 (60%)	10 (50%)	NS
Time to reperfusion (hour)	$5\mathrm{\hspace{0.17em}\hspace{0.17em}}\pm 4$	$5\pm 3$	NS
Troponin peak	$4\mathrm{\hspace{0.17em}\hspace{0.17em}}\pm \mathrm{\hspace{0.17em}\hspace{0.17em}}2$	$3.5\pm 1$	NS
Treatment at discharge
Antiaggregants	20 (100%)	20 (100%)	NS
B-blockers	12 (60%)	10 (50%)	NS
ACE-inhibitors	20 (100%)	20 (100%)	NS
Diuretics	16 (80%)	15 (75%)	NS
Nitrates	12 (60%)	12 (60%)	NS
Statins	20 (100%)	20 (100%)	NS
Baseline echocardiographic features
LVEDV (mL)	$93\mathrm{\hspace{0.17em}\hspace{0.17em}}\pm \mathrm{\hspace{0.17em}\hspace{0.17em}}7$	$97\mathrm{\hspace{0.17em}\hspace{0.17em}}\pm \mathrm{\hspace{0.17em}\hspace{0.17em}}6$	NS
LVESV (mL)	$53\mathrm{\hspace{0.17em}\hspace{0.17em}}\pm \mathrm{\hspace{0.17em}\hspace{0.17em}}7$	$56\mathrm{\hspace{0.17em}\hspace{0.17em}}\pm \mathrm{\hspace{0.17em}\hspace{0.17em}}7$	NS
EF (%)	$44\mathrm{\hspace{0.17em}\hspace{0.17em}}\pm \mathrm{\hspace{0.17em}\hspace{0.17em}}4$	$42\pm \mathrm{\hspace{0.17em}\hspace{0.17em}}5$	NS

LVEDV: left ventricular end-diastolic volume; LVESV: left ventricular end-systolic volume; EF: ejection fraction. NS: not significant; **$P<.01$.